Can a patient with C3 glomerulopathy safely take low‑dose aspirin (81 mg daily) for cardiovascular protection?

Can a Patient with C3 Glomerulopathy Take Low-Dose Aspirin for Cardiovascular Protection?

A patient with C3 glomerulopathy (C3G) can take aspirin 81 mg daily for cardiovascular protection, but this decision requires careful assessment of their bleeding risk, particularly their kidney function and concurrent medications.

Risk-Benefit Framework

The decision hinges on balancing cardiovascular benefit against bleeding risk in the context of kidney disease. C3G is a complement-mediated glomerulonephritis that often progresses to chronic kidney disease (CKD), and CKD itself substantially modifies both the benefits and risks of aspirin therapy.

Cardiovascular Benefits in CKD

For patients with CKD stages 3-5 (which many C3G patients develop), low-dose aspirin provides significant cardiovascular protection. A 2025 meta-analysis demonstrated that aspirin reduces major adverse cardiovascular events (RR 0.76), cardiovascular mortality (RR 0.60), and all-cause mortality (RR 0.78) in CKD stages 3-5 1. The benefit is particularly pronounced when eGFR falls below 45 mL/min/1.73m², where aspirin reduces myocardial infarction risk by 53% (RR 0.47) and cardiovascular mortality by 53% (RR 0.47) 1.

Bleeding Risk Considerations

However, aspirin increases major bleeding risk by 50% (RR 1.50) in CKD patients, with risk escalating as kidney function declines 1. The 2018 KDIGO guidelines explicitly state that aspirin is indicated for secondary prevention but not primary prevention in CKD (Grade 2B), and the 2019 ACC/AHA guidelines identify CKD as a condition associated with increased bleeding risk 2, 3.

Clinical Decision Algorithm

Step 1: Assess Cardiovascular Indication

• Secondary prevention (prior MI, stroke, or known coronary disease): Aspirin is recommended 2
• Primary prevention: Aspirin is generally not recommended in CKD unless unable to control other risk factors 3

Step 2: Evaluate Bleeding Risk Factors

The FDA label and guidelines identify key contraindications 4, 3:

• Age >70 years (avoid routine use)
• History of gastrointestinal bleeding or peptic ulcer disease
• Thrombocytopenia or coagulopathy
• Concurrent medications: NSAIDs, steroids, anticoagulants (warfarin, DOACs)
• Severe CKD (eGFR <30 mL/min/1.73m² carries highest bleeding risk)
• ≥3 alcoholic drinks daily

Step 3: Assess Current Kidney Function

For C3G patients specifically:

• If eGFR ≥45 mL/min/1.73m² and secondary prevention indication: Aspirin 81 mg daily is reasonable if no high bleeding risk factors present
• If eGFR <45 mL/min/1.73m²: Greatest cardiovascular benefit but also increased bleeding risk—requires individualized assessment weighing cardiovascular risk against bleeding risk 1
• If eGFR <30 mL/min/1.73m² or on dialysis: Bleeding risk substantially elevated; aspirin should generally be avoided for primary prevention 3, 2

Practical Recommendations for C3G Patients

For secondary cardiovascular prevention: Use aspirin 81 mg daily unless high bleeding risk factors are present. The cardiovascular mortality benefit outweighs bleeding risk in most cases 1.

For primary prevention: Aspirin is not routinely recommended. Consider only if:

• Patient has diabetes with albuminuria or multiple cardiovascular risk factors 2
• Unable to achieve optimal control of blood pressure, lipids, or glucose 3
• Age 40-70 years with estimated 10-year ASCVD risk >10% 3

Avoid aspirin if:

• Age >70 years (unless compelling secondary prevention indication) 3
• History of gastrointestinal bleeding or active peptic ulcer 4
• Concurrent anticoagulation therapy 3
• Severe thrombocytopenia or known bleeding disorder 3

Important Caveats

Dose matters: Use only 81 mg daily. Higher doses (>100 mg) increase bleeding risk without additional cardiovascular benefit 3. Daily dosing is superior to alternate-day dosing for thromboxane suppression 5.

Monitor proteinuria: C3G patients often have significant proteinuria, which is both a cardiovascular risk factor and a marker of disease activity. Aspirin decisions should be reassessed as kidney function changes 6.

Complement-targeted therapies: Newer C3G treatments (pegcetacoplan, iptacopan) may improve kidney function and reduce proteinuria 6, potentially modifying the risk-benefit calculation for aspirin over time.

Transplant considerations: If the C3G patient has received a kidney transplant, they are typically on immunosuppression (often including steroids), which increases bleeding risk with aspirin 3. Post-transplant patients generally have secondary prevention indications but require careful bleeding risk assessment.